Samsrita Labs Ltd

Samsrita Labs Ltd has announced the closure of its trading window for dealing in the company's securities. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015 and the company's internal code of conduct. The window will be shut from July 1, 2026, until 48 hours after the declaration of the un-audited standalone and consolidated financial results for the quarter ending June 30, 2026. All designated persons, their immediate relatives, and connected persons are prohibited from trading during this period. The company will separately announce the date of the Board of Directors' meeting where the financial results will be discussed and approved.

Samsrita Labs Ltd reports no deviation or variation in the use of proceeds raised through a preferential issue for the quarter ended March 31, 2026. The funds, amounting to ₹339.10 lakhs raised on July 18, 2025, were allocated to working capital, investments, repayment of unsecured loans, and general corporate purposes. The Audit Committee reviewed and confirmed the statement on May 29, 2026.

Samsrita Labs Ltd appointed M/s Tungala & Co., Chartered Accountants, as the Internal Auditors for the financial year 2026-27, following the recommendation of the Audit Committee. This decision was made during the Board of Directors meeting held on May 29, 2026. The board also approved the write-off of outstanding sundry creditors amounting to ₹3,14,676 and trade receivables/doubtful debts of ₹2,08,99,089 due from M/s Mangala Savitri Bizcon Private Limited.

Samsrita Labs Ltd announced its audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The Board of Directors also approved the appointment of M/s Tungala & Co. as the Internal Auditors for FY 2026-27 and the write-off of outstanding sundry creditors and trade receivables.

Samsrita Labs Ltd's board meeting on May 29, 2026, approved audited financial results (standalone and consolidated) for the quarter and year ended March 31, 2026. M/s Tungala & Co. was appointed as the Internal Auditors for FY 2026-27. The board also approved the write-off of long outstanding Sundry Creditors amounting to ₹3,14,676 and trade receivables/doubtful debts of ₹2,08,99,089 due from M/s Mangala Savitri Bizcon Private Limited.

Samsrita Labs Ltd has scheduled a Board of Directors meeting on May 29, 2026, to consider and approve the audited financial statements (standalone and consolidated) for the quarter and year ended March 31, 2026. The trading window remains closed until 48 hours after the declaration of the audited financial results.

Samsrita Labs Ltd responded to an email from BSE dated April 17, 2026, regarding unusual price movement in its shares. The company clarified that it has duly intimated the exchange of all events and price-sensitive information as required by Regulation 30 and other applicable regulations of SEBI (LODR) Regulations, 2015. Samsrita Labs stated that it has not withheld any information that could influence the scrip's price or volume behavior. The company attributes the share price movement purely to market conditions, over which it has no control or knowledge of the underlying reasons. Samsrita Labs reiterated its commitment to adhering to SEBI (LODR) Regulations, 2015, and assured the stock exchange of timely disclosures.

Samsrita Labs Limited has announced the closure of the trading window for dealing in the securities of the company. The closure is in accordance with the Company's Code of Conduct for Prevention of Insider Trading under SEBI (Prohibition of Insider Trading) Regulations, 2015. The trading window will remain closed from 01.04.2026 till 48 hours after the declaration of Audited standalone and Consolidated Financial Results of the Company for the Quarter and year ending 31.03.2026 for all designated persons, their immediate relatives and all connected persons covered under the Company’s Code of Conduct. The designated persons have been informed not to trade in the securities of the company during the closure period.

Samsrita Labs Ltd, a company in the human healthcare segment, is strategically expanding into the Pet Animal Healthcare and Wellness segment. This decision is driven by the robust growth of the Indian pet care market, the 'Pet Humanization' trend, and the strategic synergy with the company's existing healthcare segment. The company aims to apply its high healthcare standards to the pet wellness space, providing professional grooming and therapeutic services. This expansion is expected to create long-term value for the shareholders by tapping into a high-growth, high-margin consumer segment that complements the existing healthcare segment.

Samsrita Labs Ltd. has released a statement of deviation or variation for the quarter ended 31.12.2025, stating that there is no deviation or variation in use of proceeds raised through preferential issue. The audit committee of the company has reviewed the statement on 06.02.2026. The company has not raised any funds through preferential issues in the quarter ended 31-12-2025.